Brief: Can-Fite’S Phase 3 Psoriasis Study Achieves 75% Enrollment, Results Expected Q4 2021
29/04/2021 13:54
April 29 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE’S PHASE III PSORIASIS STUDY ACHIEVES 75%
ENROLLMENT;
TOP LINE RESULTS EXPECTED Q4 2021
* CAN FITE BIOPHARMA LTD - EXPECTS TO COMPLETE ENROLLMENT IN
Q3
2021 AND REPORT TOPLINE RESULTS IN Q4 2021 FOR PHASE III COMFORT
STUDY
Source text for Eikon: ID:nBwbLW6kZa
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage